Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 25, 2021 08:05 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris Reports Fourth Quarter and Full Year 2020 Financial Results

– Company executing on growth strategy to build-out pipeline of development assets – Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q2 2021 ...
March 22, 2021 16:05 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Requirement

CHARLESTON, S.C., March 22, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
March 15, 2021 08:05 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerzburg for Development of a Potential Oral Prophylactic Bacterial Vaccine Against COVID-19

- Company secures next step to continue to build-out pipeline of assets - Company exercised its option to enter into an exclusive license of intellectual property for the development of a...
March 11, 2021 08:05 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary Hypoparathyroidism

– Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone (PTH) fusion polypeptides covering the field of human use which...
February 24, 2021 08:05 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris to Present at the H.C. Wainwright Global Life Sciences Conference

CHARLESTON, S.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing...
February 19, 2021 13:25 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris Announces Closing of $29.7 Million Bought Deal Offering of Common Shares

CHARLESTON, S.C., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
February 16, 2021 22:00 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris Increases Previously Announced Bought Deal Offering of Common Shares to $29.7 Million

CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
February 16, 2021 17:19 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris Announces $10.0 Million Bought Deal Offering of Common Shares

CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
February 02, 2021 07:30 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg

- Company secures next step to continue to build-out pipeline of assets - University researchers developed a proprietary and orally active bacterial vaccine platform technology currently undergoing...
January 28, 2021 08:05 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics

- Company licenses exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific immunosuppressive therapeutic proteins for the potential treatment of neuromyelitis...